Pure Global AI
NCT06353646Not yet recruiting

XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer

Efficacy and Safety Trial of XH001 (Neoantigen Cancer Vaccine) Sequential Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer
Wu WenmingClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
XH001
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Wu Wenming
Funder
Peking Union Medical College Hospital
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Dec 01, 2026
Enrollment
12 participants
Primary outcome

DFS,1-year DFS rate,MFS,OS

Summary

This is a single-center, open label, single-arm, investigator-initiated study to evaluate the
 efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with
 ipilimumab and chemotherapy in pancreatic cancer patients following surgical resection.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06353646
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06353646 through Pure Global AI's free database. This phase not specified trial is sponsored by Wu Wenming and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.